Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Lisata Therapeutics, Inc. - Common Stock
(NQ:
LSTA
)
3.480
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lisata Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events
October 31, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis
October 28, 2024
Strategic partnership explores therapeutic effect of Lisata’s novel cyclic peptide product candidate, certepetide, in combination with bevacizumab
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events
October 03, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Earnings Scheduled For November 12, 2024
↗
November 12, 2024
Via
Benzinga
Earnings Outlook For Lisata Therapeutics
↗
November 11, 2024
Via
Benzinga
Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration
November 06, 2024
Study will investigate the benefits of combining Lisata's novel product candidate, certepetide, with ValoTx's platform technology, PeptiCRAd, and a checkpoint inhibitor in preclinical tumor models
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024
November 06, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial
September 17, 2024
Study arm initiated based upon enthusiasm and at the request of investigators who participated in first-line cholangiocarcinoma cohort
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events
September 09, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma
September 05, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
LSTA Stock Earnings: Lisata Therapeutics Beats EPS for Q2 2024
↗
August 12, 2024
LSTA stock results show that Lisata Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024
August 05, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy
July 18, 2024
From
Lisata Therapeutics, Inc.; Quest Diagnostics, Haystack Oncology
Via
GlobeNewswire
EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy
↗
July 18, 2024
Haystack Oncology, a Quest Diagnostics company, and Lisata Therapeutics collaborate to use Haystack MRD technology in a study of certepetide plus chemotherapy for metastatic pancreatic cancer, focusing...
Via
Benzinga
Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma
July 16, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model
July 10, 2024
Certepetide shown to promote immune cell infiltration into tumors and inhibit metastasis
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial
June 13, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events
May 28, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer
May 20, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results
May 13, 2024
Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results
Via
News Direct
Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results
May 13, 2024
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo tells Proactive's Stephen Gunnion that 2024 is a pivotal year for the oncology company, with Phase 2b ASCEND trial top-line data expected in the...
Via
TheNewswire.com
LSTA Stock Earnings: Lisata Therapeutics Beats EPS for Q1 2024
↗
May 09, 2024
LSTA stock results show that Lisata Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events
May 08, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024
May 02, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
April 23, 2024
Results of Phase 1b/2 in China reinforce global clinical development rationale and plans for LSTA1
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
April 09, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events
April 03, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
March 21, 2024
Achieves critical first step toward priority review voucher
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
